Commitments And Contingencies (Narrative) (Details) (USD $)	3 Months Ended				3 Months Ended						3 Months Ended		0 Months Ended							3 Months Ended							3 Months Ended				3 Months Ended
	Mar. 31, 2013	Sep. 30, 2012	Mar. 31, 2012	Dec. 31, 2012	Mar. 31, 2013 Teikoku Seiyaku Co., Ltd. [Member] Japanese_Facilities	Mar. 31, 2012 Teikoku Seiyaku Co., Ltd. [Member]	Mar. 31, 2013 Watson Laboratories, Inc [Member]	Aug. 03, 2012 Watson Laboratories, Inc [Member]	Mar. 31, 2013 Impax Laboratories, Inc. [Member]	May 03, 2011 Manufacturing agreement [Member] Novartis Consumer Health Inc [Member]	Mar. 31, 2013 Ventiv agreement [Member]	Mar. 31, 2012 Ventiv agreement [Member]	Sep. 25, 2012 Ventiv agreement [Member] Sales representatives [Member] field_force	Sep. 26, 2012 Ventiv agreement [Member] Sales representatives [Member] field_force	Sep. 25, 2012 Ventiv agreement [Member] District managers [Member] field_force	Sep. 26, 2012 Ventiv agreement [Member] District managers [Member] field_force	Sep. 25, 2012 Ventiv agreement [Member] Project manager [Member] field_force	Sep. 25, 2012 Ventiv agreement [Member] Trainer [Member] field_force	Sep. 25, 2012 Ventiv agreement [Member] National sales director [Member] field_force	Mar. 31, 2013 Voltaren gel agreement extending through June 30, 2012 [Member] Novartis Consumer Health Inc [Member]	Mar. 31, 2013 Voltaren Gel Agreement Extending Through June Two Thousand Thirteen [Member] Novartis Consumer Health Inc [Member]	Mar. 31, 2013 Unfavorable regulatory action [Member]	Dec. 31, 2012 Unfavorable regulatory action [Member]	Apr. 26, 2013 MCP cases [Member] Pending_Cases	Apr. 26, 2013 Propoxyphene cases [Member] Pending_Cases	Apr. 26, 2013 Vaginal mesh cases [Member] Pending_Cases	Mar. 31, 2013 Maximum [Member] Paragraph IV certification on frova [Member]	Mar. 31, 2013 Minimum [Member] Paragraph IV certification on frova [Member]	Jun. 30, 2012 Previously reported [Member] Watson Laboratories, Inc [Member]	Mar. 31, 2013 2013 Payments [Member] Watson Laboratories, Inc [Member]	Mar. 31, 2013 State of Louisiana v. Abbott Laboratories, Inc [Member]	Mar. 31, 2013 Watson Settlement Agreement [Member]	Sep. 30, 2012 Watson Settlement Agreement [Member]	Mar. 31, 2013 Grunenthal Agreement [Member] Regulatory and commercial milestone [Member]	Mar. 31, 2012 Grunenthal Agreement [Member] Regulatory and commercial milestone [Member]	Mar. 31, 2013 Patents [Member]
Commitments And Contingencies [Line Items]
Purchase commitment term (in years)										5 years
Purchase commitment, renewal term (in years)										5 years
Required minimum purchase					$ 40,300,000															$ 16,000,000	$ 4,500,000
Required minimum spending percentage of prior year sales																				13.00%
Amounts incurred by Endo for A&P Expenditures	2,100,000		3,600,000
Japanese facilities for commercial sale in the United States					2
Termination of agreement notice period (days)					30 days
Termination of agreement written notice after expiration date, (in days)					180 days
Percentage of royalty rate of net sales						6.00%
Payments for royalties					11,000,000	12,300,000
Royalty payable					11,000,000
Wholesaler price discount percentage								50.00%
Sales and promotional services employees													228	170	24	17	1	1	1
Additional milestone payment recognized																																		8,200,000	3,900,000
Expenses incurred with respect to Ventiv under the Ventiv Agreement											7,100,000	9,600,000
Payment for contingent consideration	(5,000,000)		0																																	(15,000,000)
Loss Contingency Accrual, at Carrying Value																						159,800,000	92,000,000
Loss contingency, loss in period	194,000,000	53,000,000																													4,600,000
Percentage of royalty rate of gross sales (percent)							25.00%
Other commitment, due in second year, monthly payment							12,000,000
Other commitment, due in second year																														96,000,000
Rebate percent							50.00%
Estimated litigation liability																													131,400,000			53,200,000	85,100,000
Patent litigation settlement items, net	19,227,000		0				46,200,000																									19,227,000	46,200,000
Discount rate							5.10%
Increase (decrease) in accounts payable	136,323,000		4,118,000
Accounts payable	$ 272,377,000			$ 416,882,000					$ 102,000,000
Patents expiration date																											2015	2014
Pending claims, number																								841	40	7,700
Cases on appeal																									72
Lawsuit filing period	45 days
Stay of approval period, Hatch-Waxman Act	30 months